$CBIO News

Last published 19h ago

19h agoCBIOCRESCENT BIOPHARMA, INC. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
19h agoCBIOCrescent Biopharma Reports Third Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswireCompleted dose escalation in Phase 1/2 ASCEND trial of CR-001 with more than 125 patients dosed across United States, Europe and South Korea; enrolling standard of care chemotherapy combination expansion cohorts; on track for initial monotherapy data, including antitumor response for first-line non-small cell lung cancer (NSCLC) cohort in Q1 2027
1w agoCBIOCrescent Biopharma Announces Grants of Inducement AwardsGlobeNewswireWALTHAM, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next
1w agoCBIOCrescent Biopharma to Present at November Investor ConferencesGlobeNewswireWALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next
4w agoCBIOCrescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001GlobeNewswireMore than 125 patients dosed in ASCEND across the United States, Europe and South Korea; dose escalation complete On track to report initial monotherapy data from ASCEND in Q1 2027, including antitumor response for a
1mo agoCBIOCrescent Biopharma Announces Grants of Inducement AwardsGlobeNewswireWALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next
2mo agoCBIOCrescent Biopharma Announces Grants of Inducement AwardsGlobeNewswireWALTHAM, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next
2mo agoCBIOCrescent Biopharma to Present at September Investor ConferencesGlobeNewswireWALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next
3mo agoCBIOCrescent Biopharma Announces Grants of Inducement AwardsGlobeNewswireWALTHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next
3mo agoCBIOCrescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswireEnrollment progressing in ASCEND Phase 1/2 global clinical trial evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients CR-001 + sacituzumab
3mo agoCBIOCrescent Biopharma Announces Grants of Inducement AwardsGlobeNewswireWALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next
3mo agoCBIOCrescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewswireWALTHAM, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next
4mo agoCBIOCrescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded WarrantsGlobeNewswireWALTHAM, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next
4mo agoCBIOCrescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded WarrantsGlobeNewswireWALTHAM, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next
4mo agoCBIOCrescent Biopharma Announces Grants of Inducement AwardsGlobeNewswireWALTHAM, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next
5mo agoCBIOCrescent Biopharma Announces Grants of Inducement AwardsGlobeNewswireWALTHAM, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies
5mo agoCBIOCrescent Biopharma to Present at June Investor ConferencesGlobeNewswireWALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies
5mo agoCBIOCrescent Biopharma Announces Grants of Inducement AwardsGlobeNewswireWALTHAM, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies
5mo agoCBIOTD COWEN 7TH ANNUAL ONCOLOGY INNOVATION SUMMIT: INSIGHTS FOR ASCO & EHA - CRESCENT BIOPHARMA INCEarnings Call TranscriptsGood morning and welcome once again to TD Cowan's 7th Annual Oncology Innovation Summit. I'm Phil Nadeau, one of the biotech analysts here at Cowan, and it's my pleasure to do a chat with Crescent Biopharma. We have with
5mo agoCBIOCrescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual MeetingGlobeNewswireASCEND Phase 1/2 global clinical trial evaluating CR-001 in multiple solid tumor types, including NSCLC, gastrointestinal and gynecological cancers in first-line and previously treated patients Multiple CR-001 clinical
6mo agoCBIOCrescent Biopharma Announces Grants of Inducement AwardsGlobeNewswireWALTHAM, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies
6mo agoCBIOCrescent Biopharma to Present at May Investor ConferencesGlobeNewswireWALTHAM, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies
6mo agoCBIOCrescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswireASCEND Phase 1/2 global clinical trial ongoing, evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients; first ADC combination trial with CR-001
6mo agoCBIOCrescent Biopharma Announces Grants of Inducement AwardsGlobeNewswireWALTHAM, Mass., April 24, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies
7mo agoCBIOCrescent Biopharma Announces Grants of Inducement AwardsGlobeNewswireWALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies
8mo agoCBIOCrescent Biopharma Announces Grants of Inducement AwardsGlobeNewswireWALTHAM, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies
8mo agoCBIOCrescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business HighlightsGlobeNewswireEstablished partnership with Kelun-Biotech expanding pipeline and accelerating combination strategy with CR-001, PD-1 x VEGF bispecific antibody, and multiple ADCs ASCEND Phase 1/2 global clinical trial underway to
8mo agoCBIOCrescent Biopharma to Present at March Investor ConferencesGlobeNewswireWALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies
8mo agoCBIOCrescent Biopharma Announces Grants of Inducement AwardsGlobeNewswireWALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies
8mo agoCBIOCrescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid TumorsGlobeNewswireASCEND to evaluate CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types, including NSCLC and gastrointestinal and gynecological cancers in first-line and previously treated patients Company
9mo agoCBIOCrescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026GlobeNewswireWALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies
9mo agoCBIOCrescent Biopharma Announces Grants of Inducement AwardsGlobeNewswireWALTHAM, Mass., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies
10mo agoCBIOCrescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid TumorsGlobeNewswireCR-001 IND cleared by U.S. FDA; Phase 1/2 ASCEND global clinical trial to evaluate CR-001 in first-line and previously treated patients on track to initiate in first quarter of 2026, with proof-of-concept data
10mo agoCBIOCrescent Biopharma Announces Grants of Inducement AwardsGlobeNewswireWALTHAM, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer
11mo agoCBIOCrescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid TumorsGlobeNewswirePartnership with Kelun-Biotech expands pipeline and accelerates combination strategy with CR-001, a PD-1 x VEGF bispecific antibody, and multiple antibody-drug conjugates (ADCs), generating clinical data in global
11mo agoCBIOKelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology TherapeuticsGlobeNewswireCompanies to advance CR-001, a PD-1 x VEGF bispecific antibody, and SKB105, an integrin beta-6-directed antibody-drug conjugate (ADC), in global markets and China Collaboration designed to accelerate and expand the
12mo agoCBIOCrescent Biopharma Announces Grants of Inducement AwardsGlobeNewswireWALTHAM, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer
1y agoCBIOCrescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business HighlightsGlobeNewswireIND Submission for CR-001, a PD-1 x VEGF Bispecific Antibody, on Track for Fourth Quarter of 2025 to Support Initiation of Global Phase 1 Trial in Patients with Solid Tumors Advancing ADCs in the Pipeline, with IND
1y agoCBIOCrescent Biopharma to Present at November Investor ConferencesGlobeNewswireWALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer
1y agoCBIOCrescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer's (SITC) 40th Annual MeetingGlobeNewswireCR-001 Demonstrated Cooperative Pharmacology and Robust Anti-Tumor Activity IND Submission for CR-001 On Track for Fourth Quarter of 2025 to Support Initiation of Global Phase 1 Trial in Patients with Solid Tumors
1y agoCBIOCrescent Biopharma to Present at September Investor ConferencesGlobeNewswireWALTHAM, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer
1y agoCBIOCrescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business HighlightsGlobeNewswireCompleted Merger with GlycoMimetics and Previously Announced $200 Million Private Financing Supporting Pipeline of Next Generation Therapeutics for Solid Tumors Recent Leadership Appointments Bring Deep Experience in
1y agoCBIOCrescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific OfficerGlobeNewswireSeasoned Leader Brings Deep Experience in Oncology Drug Development as Company Advances Portfolio of Next Generation Therapeutics for Solid Tumors WALTHAM, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma,
1y agoCBIOCrescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 MillionGlobeNewswireAdvancing Lead Program, CR-001, a PD-1 x VEGF Bispecific Antibody, and Developing Pipeline of Novel ADCs as Single Agents and in Combination with CR-001 On Track to Submit IND Application for CR-001 in Fourth Quarter of
2y agoCBIO GYRETotus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B FundingPR NewswireTotus Medicines, a company revolutionizing small molecule drug discovery and development using covalent libraries and AI tools, announced today that...
3y agoCBIOCatalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock SplitGlobeNewswireThe combined company will operate as "Gyre Therapeutics, Inc." with its common stock traded on Nasdaq under trading symbol "GYRE" effective Tuesday, October 31, 2023 SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) --
3y agoCBIOCatalyst Biosciences Provides Corporate UpdateGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Catalyst Biosciences Inc. (NASDAQ:CBIO) ("Catalyst" or "the Company") today provided two corporate updates. In connection with the Company's previously
3y agoCBIOGC Biopharma Signs Agreement with Catalyst Biosciences for the Acquisition of Rare Disease Pipeline in HematologyPR NewswireEntered into an acquisition deal of 3 programsYONGIN, South Korea, <
3y agoCBIOCatalyst Biosciences Completes First Steps in Reverse Merger PlanGlobeNewswireAcquires F351, a Phase 3 Drug to Treat Fibrosis Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in Subsequent Transaction Announces $7.5 Million Special
4y agoCBIOCatalyst Biosciences, Inc. Announces September 21, 2022 as the Ex-Dividend Date for Special Cash Dividend of $1.43 per shareGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) ("Catalyst," the "Company" or "we") today announced that the ex-dividend date for the special, one-time cash dividend of $1.43 per share to holders